Incomplete Inhibition of Platelet Aggregation and Glycoprotein IIb-IIIa Receptor Blockade by Abciximab: Importance of Internal Pool of Glycoprotein IIb-IIIa Receptors

Summary

Resting platelets contain a substantial internal pool of GPIIb-IIIa complexes that is exposed on the surface of activated platelets. Whether the exposure of internal GPIIb-IIIa complexes on the activated platelet surface affects therapy with GPIIb-IIIa antagonists is poorly understood. We addressed this issue in thirteen patients who underwent elective coronary stenting and received abciximab. Platelet aggregation, surface expression of GPIIb-IIIa and P-selectin, receptor blockade of GPIIb-IIIa, and platelet release in response to ADP and thrombin-receptor activating peptide (TRAP) were determined ex vivo by Lumi-aggregometry and flow cytometry before, during and after abciximab administration. We found that inhibition of aggregation and GPIIb-IIIa blockade of ADP-stimulated platelets was almost complete during abciximab administration. In contrast, when TRAP was used to stimulate platelets ex vivo aggregation was only partially inhibited, most likely due to release of internal pool of unblocked GPIIb-IIIa complexes. Using electron microscopy we found that 7E3-occupied GPIIb-IIIa complexes are internalized into the surface connected system (SCS) and the α-granules of washed platelets which was associated with a reduced degranulation of the α-granula membrane protein P-selectin. We conclude, that despite internalization of abciximab into the internal pool of GPIIb-IIIa, upon strong platelet activation with thrombin a significant amount of unblocked internal GPIIb-IIIa can be exposed on the platelet surface and mediate platelet aggregation. Incomplete blockade of the internal GPIIb-IIIa pool may limit clinical efficacy of abciximab.

Keywords

Platelets - GPIIb-IIIa - abciximab - internal pool - GPIIb-IIIa inhibitors

¹ M.G. and A.R. contributed equally to this work

• References

• 1 Harker LA. Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am J Cardiol 1987; 60: 20B-8B.
• 2 Kong DF, Califf RM, Miller DP, Molinterno DJ, White HD, Harrington RA, Tcheng JE, Lincoff AM, Hasselblad V, Topol EJ. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998; 98: 2829-35.
• 3 Foster RH, Wiseman LR. Abciximab. An updated review of its use in ischemic heart disease. Drugs 1998; 56: 629-65.
• 4 Plow EF, Ginsberg MH. Cellular adhesion: GPIIb-IIIa as a prototypic adhesion receptor. Prog Haemost Thromb 1989; 09: 117-56.
• 5 Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988; 71: 831-43.
• 6 Wencel-Drake JD, Plow EF, Kunicki TJ, Woods VL, Keller DM, Ginsberg MH. Localization of internal pools of membrane glycoproteins involved in platelet adhesive responses. Am J Pathol 1986; 124: 324-34.
• 7 Woods VL, Wolff LE, Keller DM. Resting platelets contain a substantial centrally located pool of glycoprotein IIb-IIIa complex which may be accessible to some but not other extracellular proteins. J Biol Chem 1986; 261: 15242-51.
• 8 The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96.
• 9 Gawaz M, Ruf A, Neumann FJ, Pogatsa-Murray G, Dickfeld T, Zohlnhöfer D, Schömig A. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Thromb Haemost 1998; 80: 994-1001.
• 10 Gawaz M, Neumann FJ, Schömig A. Evaluation of platelet membrane glycoproteins in coronary artery disease. Consequences for diagnosis and therapy. Circulation 1999; 99: e1-e11.
• 11 Ruf A, Schlenk RF, Maras A, Morgenstern E, Patscheke H. Contact-induced neutrophil activation by platelets in human cell suspensions and whole blood. Blood 1992; 80: 1238-46.
• 12 Ruf A, Patscheke H, Morgenstern E. Role of internalization in platelet activation induced by collagen fibers – differential effects of aspirin, cytochalasin D, and prostaglandin E₁ . Thromb Haemost 1991; 66: 708-15.
• 13 Lefkovitz J, Plow EF, Topol EJ. Platelet glycoprotein IIb-IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-9.
• 14 Morgenstern E, Ruf A, Patscheke H. Transport of anti-glycoprotein IIb/ IIIa-antibodies into the alpha-granules of unstimulated human blood platelets. Thromb Haemost 1992; 67: 121-5.
• 15 Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF. Differential inhibition of platelet aggregation induced by adenine diphosphate or a thrombin receptor-activating peptide in patients for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 1995; 26: 1665-71.
• 16 Bihour C, Durrieu-Jais C, Macchi L, Poujol C, Coste P, Besse P, Nurden P, Nurden AT. Expression of markers of platelet activation and the interpatient variation in response to abciximab. Art Throm Vasc Biol 1999; 19: 212-9.
• 17 Nurden P, Humbert M, Pitrowicz RS, Bihour C, Poujol C, Nurden AT, Kunicki TJ. Distribution of ligand-occupied alpha IIb beta 3 in resting and activated human platelets determined by expression of a novel class of ligandinduced binding site recognized by monoclonal antibody AP6. Blood 1996; 88: 887-99.
• 18 Topol EJ. Toward a new frontier in myocardial reperfusion therapy. Emerging platelet preeminence. Circulation 1998; 97: 211-8.
• 19 Gurbel PA, Serenruany VL, Shustov AR, Bahr RD, Carpo C, Ohman EM, Topol EJ. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. J Am Coll Cardiol 1998; 31: 1466-73.
• 20 Nurden P. Bidirectional trafficking of membrane glycoproteins following platelet activation in suspension. Thromb Haemost 1997; 78: 1305-15.
• 21 Isenberg WM, Bainton DF, Newman PJ. Monoclonal antibodies bound to subunits of the integrin GPIIb-IIIa are internalized and interfere with filopodia formation and platelet aggregation. Blood 1990; 76: 1564-71.
• 22 Wencel-Drake JD, Boudignon-Proudhon C, Dieter MG, Criss AB, Parise LV. Internalization of bound fibrinogen modulates platelet aggregation. Blood 1996; 87: 602-12.
• 23 Wencel-Drake JD, Frelinger LF, Dieter MG, Lam SCT. Arg-Gly-Asp (RGD)-dependent occupancy of αIIbβ3 by applaggin: evidence for internalization and cycling of a platelet integrin. Blood 1993; 81: 62-9.
• 24 Peerschke EIB. Bound fibrinogen distribution on stimulated platelets. Examination by confocal scanning laser microscopy. Am J Pathol 1995; 147: 678-87.
• 25 Loftus JC, Albrecht RM. Redistribution of the fibrinogen receptor of human platelets following surface activation. J Cell Biol 1984; 99: 822-9.
• 26 Nurden P, Poujol C, Durrieu-Jais C, Winckler J, Combrie R, Macchi L, Bihour C, Wagner C, Jordan R, Nurden AT. Labeling of the internal pool of GPIIb-IIIa in platelets by c7E3 Fab fragments: flow and endocytic mechanisms contribute to the transport. Blood 1999; 93: 1622-33.
• 27 Wencel-Drake JD, Boudognon-Proudhon-Boudignon C, Dieter MG, Criss AB, Parise LV. Internalization of bound fibrinogen modulates platelet aggregation. Blood 1996; 87: 602-12.
• 28 Cramer EM, Savidge GF, Vainchenker W, Berndt MC, Pidard D, Caen JP, Masse JM, Breton-Gorius J. Alpha-granule pool of glycoprotein IIb-IIIa in normal and pathologic platelets and megakaryocytes. Blood 1990; 75: 1220-7.
• 29 Plow EF, D’Souza SE, Ginsberg MH. Consequences of the interaction of platelet membrane glycoprotein GPIIb-IIIa and its ligands. J Lab Clin Med 1992; 120: 198-204.
• 30 Shattil SJ, Ginsberg MH. Intergrin signaling in vascular biology. J Clin Invest 1997; 100: 1-5.
• 31 Shattil SJ, Ginsberg MH, Brugge JS. Adhesive signaling in blood platelets. Curr Opin Cell Biol 1994; 06: 695-704.
• 32 Peter K, Schwarz M, Ylanne J, Kohler B, Moser M, Nordt T, Salbach P, Kubler W, Bode C. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alpha IIb-beta3) inhibitors. Blood 1998; 92: 3240-9.
• 33 Mustard JF, Perry DW, Kinlough-Rathbone RL, Packham MA. Factors responsible for ADP-induced release reaction of human platelets. Am J Physiol 1975; 228: 1757-65.
• 34 Willerson JT, Golino P, Eidt J, Campbell WB, Buja M. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation 1989; 80: 198-205.